Becton Dickinson (BDX) announced it has received FDA 510(k) clearance and Conformite Europeenne marking in the European Union for its Enteric Bacterial Panel and Enteric Bacterial Panel plus for the BD COR System.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BD’s New Vascular Access Study: What Investors Need to Know
- BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access
- Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications
- BDX’s Innovative Study on BD PosiFlush™ SafeScrub: Market Insights
- Ulta Beauty names Christopher DelOrefice CFO